Neutrophil-to-Lymphocyte Ratio as a Predictor of Worsening Renal Function in Diabetic Patients (3-Year Follow-Up Study)

REFERENCES

• Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study. Kidney Int. 1996;50(6):2041–2046.
   PubMed Web of Science ®Google Scholar
• Matsushima M, Tajima N, LaPorte RE, . Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetes Epidemiology Research International (DERI) US-Japan Mortality Study Group. Diabetologia. 1995;38(2):236–243.
   PubMedGoogle Scholar
• Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994;330(1):15–18.
   PubMed Web of Science ®Google Scholar
• Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: A cohort study. Am J Kidney Dis. 2007;50(5):721–732.
   PubMed Web of Science ®Google Scholar
• Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. J Am Med Assoc. 2005;294(14):1782–1787.
   Web of Science ®Google Scholar
• Pavkov ME, Knowler WC, Bennett PH, Looker HC, Krakoff J, Nelson RG. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int. 2006;70(10):1840–1846.
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Hostetter T, Bakris GL, . Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK). Am J Kidney Dis. 2003;42(4):617–622.
   PubMed Web of Science ®Google Scholar
• Araki S, Haneda M, Koya D, . Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007;56(6):1727–1730.
   PubMed Web of Science ®Google Scholar
• Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19(11):2784–2788.
   PubMed Web of Science ®Google Scholar
• Choudhary N, Ahlawat RS. Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: New evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis. 2008;2(2):72–79.
   PubMedGoogle Scholar
• Kuhad A, Sachdeva AK, Chopra K. Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol. J Agric Food Chem. 2009;57(14):6123–6128.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–442.
   PubMed Web of Science ®Google Scholar
• Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond). 2009;116(6):479–492.
   PubMed Web of Science ®Google Scholar
• Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008;93(7):817–824.
   PubMed Web of Science ®Google Scholar
• Lewis A, Steadman R, Manley P, . Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol Histopathol. 2008;23(6):731–739.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Zhang SX, Mott R, . Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294(5):F1166–F1173.
   PubMed Web of Science ®Google Scholar
• Astrup AS, Tarnow L, Pietraszek L, . Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: Association with mortality and decline of glomerular filtration rate. Diabetes Care. 2008;31(6):1170–1176.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Burford JL, Dominguez JH. Postischemic inflammatory syndrome: A critical mechanism of progression in diabetic nephropathy. Am J Physiol Renal Physiol. 2009;297(4):F923–F931.
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Hovind P, . Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest. 2008;68(8):731–738.
   PubMed Web of Science ®Google Scholar
• Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol. 2009;29(3):274–282.
   PubMed Web of Science ®Google Scholar
• Ko GJ, Kang YS, Han SY, . Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23(9):2750–2760.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Jarque A, Muros M, Mora C, Garcia J. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 2009;20(2):165–173.
   PubMed Web of Science ®Google Scholar
• Ogawa S, Kobori H, Ohashi N, . Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights. 2009;4:97–102.
   PubMedGoogle Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, . Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Krauth M, Huff JW, . Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33(5):469–476.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, . Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365(4):327–336.
   PubMed Web of Science ®Google Scholar
• Goodman DA, Goodman CB, Monk JS. Use of the neutrophil: Lymphocyte ratio in the diagnosis of appendicitis. Am Surg. 1995;61(3):257–259.
   PubMed Web of Science ®Google Scholar
• Gurm HS, Bhatt DL, Lincoff AM, . Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: Insights from the EPIC, EPILOG, and EPISTENT trials. Heart. 2003;89(10): 1200–1204.
   PubMed Web of Science ®Google Scholar
• Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653–657.
   PubMed Web of Science ®Google Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts–rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5–14.
   PubMedGoogle Scholar
• Gibson PH, Croal BL, Cuthbertson BH, . Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J. 2007;154(5):995–1002.
   PubMed Web of Science ®Google Scholar
• Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: The NHANES-I epidemiologic follow-up study. Ann Epidemiol. 2005;15(4):266–271.
   PubMed Web of Science ®Google Scholar
• Tsai JC, Sheu SH, Chiu HC, . Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2007;23(2):111–118.
   PubMed Web of Science ®Google Scholar
• Chung FM, Tsai JC, Chang DM, Shin SJ, Lee YJ. Peripheral total and differential leukocyte count in diabetic nephropathy: The relationship of plasma leptin to leukocytosis. Diabetes Care. 2005;28(7):1710–1717.
   PubMed Web of Science ®Google Scholar
• Nunez J, Nunez E, Bodi V, . Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol. 2008;101(6):747–752.
   PubMed Web of Science ®Google Scholar
• Azab B, Zaher M, Weiserbs KF, . Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106(4):470–476.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Dominguez JH. Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol. 2010;32(5):469–475.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Dominguez JH. Treatment of the post-ischemic inflammatory syndrome of diabetic nephropathy. Nephrol Dial Transplant. 2010;25(10):3204–3212.
   PubMed Web of Science ®Google Scholar
• De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10(15):4895–4900.
   PubMed Web of Science ®Google Scholar
• Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: Potential implications for tumor progression. Cancer Res. 2005;65(19):8896–8904.
   PubMed Web of Science ®Google Scholar
• Maric-Bilkan C, Flynn ER, Chade AR. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am J Physiol Renal Physiol. 2011;302(3):F308–F315.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009;58(7):1471–1478.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Hato F, Yamane T, . Increased spontaneous adherence of neutrophils from type 2 diabetic patients with overt proteinuria: Possible role of the progression of diabetic nephropathy. Diabetes Care. 2000;23(3):417–418.
   PubMed Web of Science ®Google Scholar
• Bolignano D, Lacquaniti A, Coppolino G, . Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337–344.
   PubMed Web of Science ®Google Scholar
• Bolignano D, Lacquaniti A, Coppolino G, . Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009;32(2):91–98.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Rodriguez-Ayala E, Massy ZA, . Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2006;1(2):281–287.
   PubMed Web of Science ®Google Scholar
• Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol. 1997;79(6):812–814.
   PubMed Web of Science ®Google Scholar
• Ommen SR, Hodge DO, Rodeheffer RJ, McGregor CG, Thomson SP, Gibbons RJ. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation. 1998;97(1):19–22.
   PubMed Web of Science ®Google Scholar